CJC-1295 no DAC

Growth Hormone & IGF-1 Elevation

• Potently increases endogenous GH secretion while maintaining pulsatility.
• Elevates circulating IGF-1, driving downstream anabolic and metabolic effects.
• Short-acting profile avoids prolonged desensitization.

Muscle Growth & Performance

• Enhances protein synthesis, lean mass accrual, and recovery.
• Supports exercise capacity and skeletal muscle hypertrophy in GH-deficient models.

Fat Loss & Metabolic Regulation

• Promotes lipolysis and reduces visceral adiposity.
• Improves metabolic health markers (glucose control, lipid metabolism).

Tissue Repair & Recovery

• Increases collagen synthesis in tendons, ligaments, and muscle.
• Supports connective tissue repair, joint resilience, and wound healing.

Bone & Skeletal Health

• Stimulates osteoblast activity and bone mineralization.
• Reverses low bone turnover in GH-deficient states.

Cognition & Neuroprotection

• GHRH analog studies show improvements in memory and executive function.
• Supports restorative sleep cycles and CNS resilience.

Anti-Aging & Longevity Research

• Counters the age-related decline in GH/IGF-1.
• Improves body composition, vitality, and regenerative capacity.
• Provides a physiological GH “boost” without shutting down endogenous production.

To maximize outcomes in experimental settings, researchers often combine CJC-1295 (No DAC) with complementary peptides that act through distinct but overlapping pathways in the GH/IGF-1 axis, tissue repair, or metabolic regulation. Below is a summary of notable peptide synergies:

CJC-1295 (No DAC) Synergistic Compounds

Potential Research Use Cases for CJC-1295 (No DAC) Combinations

• Muscle Growth & Anabolism: CJC-1295 + Ipamorelin / GHRP-2 / IGF-1 LR3
• Tissue Regeneration & Recovery: CJC-1295 + TB-500 / BPC-157 / GHK-Cu
• Metabolic Health & Fat Reduction: CJC-1295 + AOD-9604 / Ipamorelin
• Neurocognitive & Sleep Studies: CJC-1295 + NAD⁺ / Selank / Semax
• Longevity & Anti-Aging Research: CJC-1295 + NAD⁺ / Glutathione / GHK-Cu

Key Functions of CJC-1295 (No DAC)

• Dramatically Increases GH and IGF-1: Clinical and preclinical research shows that CJC-1295 significantly boosts both GH and IGF-1 (Ref. 1). A single injection of the long-acting form raised mean plasma GH by 2–10× for 6+ days and IGF-1 by 1.5–3× for 9–11 days. Even with sustained stimulation, GH remained pulsatile — baseline GH rose ~7-fold and IGF-1 by ~45% one week later (Ref. 1).
• Enhanced Muscle Growth & Performance: By stimulating endogenous GH/IGF-1, CJC-1295 supports protein synthesis and muscle development. In growth-hormone-deficient animal models, daily dosing fully restored normal body weight and lean mass (Ref. 2). Raising GH/IGF-1 in older adults has been shown to increase lean muscle mass, strength, and physical performance (Ref. 5).
• Fat Loss and Metabolic Health: Elevated GH enhances lipolysis and reduces adipose stores. A 6-month GHRH-analog trial cut visceral abdominal fat by ~15% and decreased liver fat in HIV-positive patients (Ref. 3). In healthy older adults, 20 weeks of GHRH-analog therapy lowered total body fat by 7.4% while doubling IGF-1 (Ref. 5). These outcomes support CJC-1295’s metabolic role in improving body composition and reducing visceral fat.
• Accelerated Tissue Repair & Recovery: GH stimulates collagen synthesis and regeneration. Increased GH from CJC-1295 may accelerate recovery from injury or training. In one study, GH therapy increased muscle and tendon collagen synthesis by up to 6-fold (Ref. 6). This suggests improved tendon, ligament, and joint strength under GH-enhancing conditions.
• Bone Density & Skeletal Growth: The GH/IGF-1 axis governs bone remodeling. CJC-1295’s elevation of GH/IGF-1 can enhance bone density and formation (Ref. 8). In GH-deficient models, daily CJC-1295 maintained normal bone mass and length (Ref. 2). Clinical GH therapy likewise increases bone mineral density and reduces fracture risk (Ref. 8).
• Cognitive Function & Neuroprotective Effects: Beyond physical outcomes, GHRH analogs improve cognition. A 20-week placebo-controlled trial found that GHRH-analog therapy enhanced executive function and memory in older adults with and without mild cognitive impairment (Ref. 4). GHRH also enhances slow-wave sleep (Ref. 7), aligning with anecdotal reports of improved rest and recovery under GH-secretagogue regimens.
• Anti-Aging & Longevity: CJC-1295’s GH-restoring properties counteract age-related declines. By improving lean mass, bone density, and fat metabolism, and supporting cognitive and metabolic health, it addresses several hallmarks of aging (Refs. 3, 5, 8). Unlike exogenous GH, CJC-1295 preserves natural feedback and pulsatility, offering a safer means of sustaining youthful hormone dynamics (Ref. 1).
  
• Safety & Tolerability: In human trials, CJC-1295 was well-tolerated up to 60 µg/kg with only mild, transient side effects (Ref. 1). No serious adverse reactions or sustained hyperglycemia occurred, and normal GH pulsatility was maintained. Mild injection-site redness or temporary tingling may appear but resolves quickly

CJC-1295 With DAC vs. Without DAC

• Half-Life and Dosing: The DAC-bound form covalently attaches to albumin, producing a 5.8–8-day half-life and once-weekly dosing (Ref. 1).
  CJC-1295 (No DAC) clears in ~30 minutes and is typically dosed 1–3 times daily to maintain rhythmic GH pulses.
• GH Release Profile: DAC versions provide continuous GH elevation; no-DAC triggers shorter, physiological bursts (Ref. 1).
  Researchers often prefer the no-DAC form when investigating precise, natural GH pulsatility.
• Potential Advantages & Drawbacks: No-DAC CJC-1295 aligns with natural hormone rhythms, avoiding constant receptor stimulation.
  DAC provides convenience but can flatten GH peaks, and prolonged exposure may increase side-effect likelihood (Ref. 1).